tirzepatide sglt2 Efficacy of versus inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study | Hepatology International heart and kidney function Prescribing pearls: A guide to

You will give yourself these injections at home once a week after training with your provider

If you were eating 2,200 calories daily and suddenly only want 1,500, your body experiences an abrupt energy deficit

Additionally, it will control your appetite, making you feel full more quickly, and less hungry after eating

trial data did not show a significant change in total daily energy expenditure

This process typically takes 6 to 12 months following Health Canada approval, creating a gap between regulatory approval and practical access for many patients

Semaglutide also has evidence for cardiovascular risk reduction, while Wegovy was approved in 2025 for MASH with moderate-to-advanced liver fibrosis